{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:20:16Z","timestamp":1793830816688,"version":"4.6.1"},"reference-count":40,"publisher":"Massachusetts Medical Society","issue":"14","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"name":"Spero Therapeutics, Inc.","id":[{"id":"https:\/\/ror.org\/05fxq1221","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2022,4,7]]},"DOI":"10.1056\/nejmoa2105462","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T17:01:31Z","timestamp":1649264491000},"page":"1327-1338","source":"Crossref","is-referenced-by-count":82,"title":["Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection"],"prefix":"10.1056","volume":"386","author":[{"given":"Paul B.","family":"Eckburg","sequence":"first","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Muir","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Critchley","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Walpole","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kwak","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Phelan","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Moore","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Jain","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Keutzer","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dane","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Melnick","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Talley","sequence":"additional","affiliation":[{"name":"From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz536"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw281"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2018.05.005"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.03.022"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.008"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2017.1380395"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223409"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy297"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06060-11"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/671740"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.022"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914433"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00346-20"},{"key":"e_1_3_5_16_2","unstructured":"Antibiotic resistance threats in the United States 2019. Atlanta: Centers for Disease Control and Prevention 2019 (https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf)."},{"key":"e_1_3_5_17_2","unstructured":"Carbapenem-resistant Enterobacteriaceae \u2014 second update: 26 September 2019. Stockholm: European Centre for Disease Prevention and Control 2019."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1720647"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa034"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2019.05.012"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496821"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02618-18"},{"key":"e_1_3_5_23_2","unstructured":"Citron DM Tyrrell KL Rubio A Goldstein EJC. In vitro activity of tebipenem (SPR859) tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria. Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02240-19"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-18"},{"key":"e_1_3_5_26_2","unstructured":"Mendes RE Rhomberg PR Huynh H Cotroneo N Rubio A Flamm RK. Antimicrobial activity of tebipenem (SPR859) against a global challenge set. Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_27_2","unstructured":"Mendes RE Rhomberg PR Watters A Cotroneo N Rubio A Flamm RK. Antimicrobial activity assessment of tebipenem (SPR859) against an isolate collection causing urinary tract infections. Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_28_2","unstructured":"Zou Y Cotroneo N Rubio A. In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM). Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_29_2","unstructured":"Grosser L Heang K Teague J et al. In vivo efficacy of tebipenem-pivoxil (SPR994) in an acute murine thigh infection caused by Escherichia coli and Klebsiella pneumoniae. Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_30_2","unstructured":"Heang K Grosser L Farrington K et al. In vivo characterization of tebipenem-pivoxil (SPR994) in a murine ascending Escherichia coli urinary tract infection model. Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_31_2","unstructured":"Teague J Corbet D Burgess E et al. In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of gram-negative bacterial infection. Presented at ASM Microbe Atlanta June 7\u201311 2018. abstract."},{"key":"e_1_3_5_32_2","unstructured":"Guidance document. Complicated urinary tract infections: developing drugs for treatment. Rockville MD: Food and Drug Administration June 2018."},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz021"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz181"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801467"},{"key":"e_1_3_5_39_2","unstructured":"Pew Charitable Trusts. National survey reveals barriers to outpatient antibiotic stewardship efforts. August 6 2020 (https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/issue-briefs\/2020\/08\/national-survey-reveals-barriers-to-outpatient-antibiotic-stewardship-efforts)."},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710926"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2105462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:18:22Z","timestamp":1749669502000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2105462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":40,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,4,7]]}},"alternative-id":["10.1056\/NEJMoa2105462"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2105462","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}